human clusterin quantikine elisa kit  (Bio-Techne corporation)

Journal: Frontiers in Endocrinology

Article Title: Associations of circulating apolipoprotein J and myostatin with sarcopenia in older adults with and without type 2 diabetes: a cross-sectional study

doi: 10.3389/fendo.2025.1592112

Figure Lengend Snippet: Age- and sex-adjusted serum ApoJ and MSTN levels according to Sarcopenia, severe Sarcopenia, and components of Sarcopenia. (A) ApoJ levels according to sarcopenia status and its components. (B) MSTN levels according to sarcopenia status and its components. * indicates a p-value of <0.05; ** indicates a p-value of <0.01 when comparing groups. ASMI, appendicular skeletal muscle mass index; ApoJ, apolipoprotein J; HS, handgrip strength; MSTN, myostatin; PP, physical performance.

Article Snippet: Serum levels of MSTN (pg/ml) were measured using the Human Myostatin Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, Minnesota, USA, Catalog # DGDF80) according to the manufacturer’s protocol ( ) Serum levels of ApoJ (ug/ml) were measured using the Human Clusterin Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, Minnesota, Catalog # DCLU00) following the manufacturer’s protocol.

Techniques:

Journal: Molecular Neurodegeneration

Article Title: Alzheimer’s disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication

doi: 10.1186/s13024-025-00840-1

Figure Lengend Snippet: AD risk SNP rs1532278 shows allele-specific open chromatin (ASoC) and cis-regulates CLU expression in iGlut. A Schematic research design. ATAC-seq was performed to identify OCRs and GWAS risk SNPs that showed ASoC in iPSC Glutaminergic (iGlut), GABAergic (iGABA), and dopaminergic (iDA) neurons, and microglia (iMG) and astrocytes (iAst), which is followed by transcription factor (TF) binding prediction to confirm putative functional AD risk SNP, CRIPSR-cas9 SNP editing, and functional assays in cells. B ASoC mapping identifies intronic rs1532278 as a putatively functional SNP among several other GWAS risk SNPs equivalently associated with AD at the CLU locus. Note that rs1532278 is the only SNP within the neuronal OCR with a stronger OCR peak in iGlut. C T and C alleles of rs1532278 show differential allelic ATAC-seq reads (i.e., ASoC) in iGlut. The bottom panel shows the two most conserved TF binding motifs at the SNP site. D Schematic CLU gene structure near rs1532278 (upper panel) and a diagram showing CRISPR-Cas9 editing of rs1532278 in two iPSC lines (CD05 and CD07; T/C) to covert T/C lines to isogenic T/T and C/C lines (middle panel, representative Sanger sequencing result from CD07 line). Representative images of iGlut (CD07 line) of all three genotypes are also shown (bottom panel); MAP2 and HuNu (human nuclear antigen) staining shows the morphology of iGlut and neuron purity in iGlut-mAst co-cultures. E – F ISL2 ChIP-qPCR on day 30 iGlut-mAst co-cultures. n = 3 biological replicates from one clone per line of one independent differentiation. G - H ISL2 siRNA knockdown in day- 30 pure iGlut (T/T) cultures. Samples of 72 h post-siRNA transfection were used for qPCR. n = 3 biological replicates from one clone per line of one independent differentiation. I Neuronal CLU mRNA level in isogenic iGlut-mAst co-cultures of different genotype of rs1532278 (human-specific CLU qPCR assay was used). n = 6 biological replicates per group (2–3 clones per line and 2–3 biological replicates for each clone) from two independent differentiations of each line. J Secreted CLU (sCLU) detected by ELISA from the supernatant of iGlut-mAst co-cultures. n = 4 biological replicates per group (2 clones per line and 2 biological replicates per clone) from two independent differentiations of each line. K - L Immunofluorescence staining of CLU in day 25 pure iGlut cultures. n = 6–7 coverslips per group (In total: 2 clones per line and 3–4 coverslips for each clone and 3–5 images per coverslip; shown are example images of CD05) from two independent differentiations of each line. Data, mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Scale bars are indicated in each image

Article Snippet: ELISA quantifications of human CLU (R&D system, DCLU00, specific for human CLU), human Aβ 1–40 (R&D system, DAB140B), human Aβ 1–42 (R&D system, DAB142), and mouse CLU (R&D system, MCLU00, specific for mouse CLU) were performed according to the vendors’ protocol.

Techniques: Expressing, Binding Assay, Functional Assay, CRISPR, Sequencing, Staining, ChIP-qPCR, Knockdown, Transfection, Clone Assay, Enzyme-linked Immunosorbent Assay, Immunofluorescence

Journal: Molecular Neurodegeneration

Article Title: Alzheimer’s disease protective allele of Clusterin modulates neuronal excitability through lipid-droplet-mediated neuron-glia communication

doi: 10.1186/s13024-025-00840-1

Figure Lengend Snippet: AD risk SNP rs1532278 shows allele-specific open chromatin (ASoC) and cis-regulates CLU expression in iGlut. A Schematic research design. ATAC-seq was performed to identify OCRs and GWAS risk SNPs that showed ASoC in iPSC Glutaminergic (iGlut), GABAergic (iGABA), and dopaminergic (iDA) neurons, and microglia (iMG) and astrocytes (iAst), which is followed by transcription factor (TF) binding prediction to confirm putative functional AD risk SNP, CRIPSR-cas9 SNP editing, and functional assays in cells. B ASoC mapping identifies intronic rs1532278 as a putatively functional SNP among several other GWAS risk SNPs equivalently associated with AD at the CLU locus. Note that rs1532278 is the only SNP within the neuronal OCR with a stronger OCR peak in iGlut. C T and C alleles of rs1532278 show differential allelic ATAC-seq reads (i.e., ASoC) in iGlut. The bottom panel shows the two most conserved TF binding motifs at the SNP site. D Schematic CLU gene structure near rs1532278 (upper panel) and a diagram showing CRISPR-Cas9 editing of rs1532278 in two iPSC lines (CD05 and CD07; T/C) to covert T/C lines to isogenic T/T and C/C lines (middle panel, representative Sanger sequencing result from CD07 line). Representative images of iGlut (CD07 line) of all three genotypes are also shown (bottom panel); MAP2 and HuNu (human nuclear antigen) staining shows the morphology of iGlut and neuron purity in iGlut-mAst co-cultures. E – F ISL2 ChIP-qPCR on day 30 iGlut-mAst co-cultures. n = 3 biological replicates from one clone per line of one independent differentiation. G - H ISL2 siRNA knockdown in day- 30 pure iGlut (T/T) cultures. Samples of 72 h post-siRNA transfection were used for qPCR. n = 3 biological replicates from one clone per line of one independent differentiation. I Neuronal CLU mRNA level in isogenic iGlut-mAst co-cultures of different genotype of rs1532278 (human-specific CLU qPCR assay was used). n = 6 biological replicates per group (2–3 clones per line and 2–3 biological replicates for each clone) from two independent differentiations of each line. J Secreted CLU (sCLU) detected by ELISA from the supernatant of iGlut-mAst co-cultures. n = 4 biological replicates per group (2 clones per line and 2 biological replicates per clone) from two independent differentiations of each line. K - L Immunofluorescence staining of CLU in day 25 pure iGlut cultures. n = 6–7 coverslips per group (In total: 2 clones per line and 3–4 coverslips for each clone and 3–5 images per coverslip; shown are example images of CD05) from two independent differentiations of each line. Data, mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Scale bars are indicated in each image

Article Snippet: ELISA quantifications of human CLU (R&D system, DCLU00, specific for human CLU), human Aβ 1–40 (R&D system, DAB140B), human Aβ 1–42 (R&D system, DAB142), and mouse CLU (R&D system, MCLU00, specific for mouse CLU) were performed according to the vendors’ protocol.

Techniques: Expressing, Binding Assay, Functional Assay, CRISPR, Sequencing, Staining, ChIP-qPCR, Knockdown, Transfection, Clone Assay, Enzyme-linked Immunosorbent Assay, Immunofluorescence

Journal: Medicina

Article Title: Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide

doi: 10.3390/medicina61050807

Figure Lengend Snippet: Kidney injury biomarkers associated with tubular atrophy and interstitial damage. In particular, CLU and MCP-1 are associated with tubular injury, while MMP-9 is linked to interstitial fibrosis. (Monocyte Chemotactic Protein-1 (MCP-1); Matrix MetalloProteinase-9 (MMP-9); clusterin (CLU)).

Article Snippet: MCP-1, MMP-9 and clusterin concentrations were measured using commercially available sandwich ELISA kits (MCP-1: DCP00, MMP-9: DMP900; Clusterin: DCLU00; R&D Systems, Minneapolis, MN, USA).

Techniques:

Journal: Medicina

Article Title: Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide

doi: 10.3390/medicina61050807

Figure Lengend Snippet: Changes in urinary excretion of clusterin ( A , B ), MCP-1 ( C , D ) and MMP-9 ( E , F ) three months after starting on TRB treatment in RD and OD IgAN patients, respectively (Monocyte Chemotactic Protein-1 (MCP-1); Matrix MetalloProteinase-9 (MMP-9); clusterin (CLU), targeted-release budesonide (TRB), recent diagnosis (RD), old diagnosis (OD), IgA nephropathy (IgAN)).

Article Snippet: MCP-1, MMP-9 and clusterin concentrations were measured using commercially available sandwich ELISA kits (MCP-1: DCP00, MMP-9: DMP900; Clusterin: DCLU00; R&D Systems, Minneapolis, MN, USA).

Techniques: Biomarker Discovery

Journal: Medicina

Article Title: Prognostic Value of Urinary Biomarkers in Proteinuria Progression in IgA Nephropathy Patients Treated with Budesonide

doi: 10.3390/medicina61050807

Figure Lengend Snippet: Changes in kidney function ( A , B ), and proteinuria ( C , D ) during the 10 months administration of TRB treatment in RD or OD IgAN patients (Monocyte Chemotactic Protein-1 (MCP-1); Matrix MetalloProteinase-9 (MMP-9); clusterin (CLU), Targeted-release budesonide (TRB), recent diagnosis (RD), old diagnosis (OD), IgA nephropathy (IgAN).

Article Snippet: MCP-1, MMP-9 and clusterin concentrations were measured using commercially available sandwich ELISA kits (MCP-1: DCP00, MMP-9: DMP900; Clusterin: DCLU00; R&D Systems, Minneapolis, MN, USA).

Techniques: Biomarker Discovery